US2007117791A1PendingUtilityA1
Bicyclic compounds
Est. expiryOct 23, 2023(expired)· nominal 20-yr term from priority
A61P 43/00A61P 25/00A61P 25/36A61P 25/06A61P 25/28A61P 25/04A61P 25/16A61P 25/08A61P 25/14A61P 25/18A61P 25/24A61P 25/22A61P 27/02A61P 21/04C07D 223/16A61P 19/08A61K 31/416A61K 9/0019A61K 9/0053C07D 213/16
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for making and using novel benzazepine derivatives of the following formula: wherein R 1 , R 2 , R 3 , R 4 and R 5 , X, X′, Y and Y′ are as defined in the description and claims, processes for their preparation, pharmaceutical compositions containing said derivatives and their use for the preparation of medicaments useful for the prevention and treatment of diseases in which selective inhibition of monoamine oxidase B activity plays a role or is implicated.
Claims
exact text as granted — not AI-modified1 . A compound of formula I
wherein
R 1 is hydrogen or methyl;
R 2 is hydrogen, (C 1 -C 3 )-alkyl, —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R;
R 3 , R 4 and R 5 are each independently hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 ,
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
or a pharmaceutically acceptable salt thereof.
2 . The compound of formula I according to claim 1 wherein R 1 is hydrogen.
3 . The compound of formula I according to claim 1 wherein R 2 is hydrogen.
4 . The compound of formula I according to claim 1 wherein R 2 is —CH 3 , —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R 6 wherein R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 .
5 . The compound of formula I according to claim 4 wherein R 2 is —CH 3 , —CH 2 C(O)NH 2 or —CH(CH 3 )C(O)NH 2 .
6 . The compound of formula I according to claim 4 wherein R 2 is —S(O) 2 CH 3 or —C(O)R 6 , wherein R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 .
7 . The compound of formula I according to claim 1 wherein R 3 , R 4 and R 5 independently are hydrogen or halogen.
8 . The compound of formula I according to claim 7 wherein R 3 , R 4 , and R 5 are hydrogen.
9 . The compound of formula I according to claim 7 wherein R 3 and R 4 are hydrogen and R 5 is fluorine.
10 . The compound of formula I according to claim 7 wherein R 3 , R 4 , and R 5 are fluorine.
11 . The compound of formula I according to claim 7 wherein R 3 is hydrogen and R 4 and R 5 are fluorine.
12 . The compound of formula I according to claim 1 wherein X—X′ is —CH 2 —CH 2 — and Y—Y′ is —CH 2 —C(O)—.
13 . The compound of formula I according to claim 1 wherein X—X′ is —CH═CH— and Y—Y′ is —CH 2 —C(O)—.
14 . The compound of formula I according to claim 1 wherein
R 1 is hydrogen; R 2 is hydrogen, —CH 3 , —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R 6 ; R 3 , R 4 and R 5 are each independently hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl; R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 , X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and Y—Y′ is —CH 2 —C(O)—; or a pharmaceutically acceptable salt thereof.
15 . The compound of formula I according to claim 1 wherein
R 1 is hydrogen; R 2 is —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R 6 ; R 3 is halogen; R 4 and R 5 are each independently hydrogen or halogen; R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 ; and X—X′ is —CH 2 —CH 2 —; and Y—Y′ is —CH 2 —C(O)—.
16 . The compound of formula I according to claim 1 wherein
R 1 is hydrogen; R 2 is hydrogen, CH 3 , —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R 6 ; R 3 , R 4 and R 5 are each independently hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl; R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 , X—X′ is —CH═CH—; and Y—Y′ is —CH 2 —C(O)—.
17 . The compound of formula I according to claim 1 wherein
R 1 is hydrogen; R 2 is hydrogen, CH 3 or —C(O)R 6 ; R 3 is halogen; R 4 and R 5 are each independently hydrogen or halogen; R 6 is —CH 3 or —CH 2 OCH 3 ; X—X′ is —CH═CH—; and Y—Y′ is —CH 2 —C(O)—.
18 . The compound of formula I according to claim 1 wherein
R 1 is hydrogen; R 2 is hydrogen, CH 3 , —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R 6 ; R 3 , R 4 and R 5 are each independently hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl; R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 , X—X′ is —CH 2 —CH 2 —; and Y—Y′ is —CH 2 —C(O)—.
19 . The compound of formula I according to claim 1 wherein
R 1 is hydrogen; R 2 is hydrogen; R 3 is halogen; R 4 and R 5 are each independently hydrogen or halogen; X—X′ is —CH 2 —CH 2 —; and Y—Y′ is —CH 2 —C(O)—.
20 . The compound of formula I according to claim 1 selected from
8-(3-fluoro-benzyloxy)-1,3-dihydro-benzo [d]azepin-2-one, 8-(3-fluoro-benzyloxy)-3-methyl-1,3-dihydro-benzo [d]azepin-2-one, 8-(3-fluoro-benzyloxy)-3-methoxyacetyl-1,3-dihydro-benzo [d]azepin-2-one 3-acetyl-8-(3-fluoro-benzyloxy)-1,3-dihydro-benzo [d]azepin-2-one, and 8-(3-fluoro-benzyloxy)-1,3,4,5-tetrahydro-benzo [d]azepin-2-one.
21 . A process for the preparation of a compound of formula I in accordance with claim 1
wherein
R 1 is hydrogen or methyl;
R 2 is hydrogen;
R 3 , R 4 and R 5 independently are hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
comprising cleaving a protecting group P 1 off a compound of formula II
wherein P 1 is a protecting group selected from the group consisting of a tert-butoxycarbonyl, a methoxycarbonyl or 9-fluorenyl-methoxycarbonyl group.
22 . A process for the preparation of a compound of formula I in accordance with claim 1
wherein
R 1 is hydrogen or methyl;
R 2 is hydrogen, (C 1 -C 3 )-alkyl, —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R 6 ;
R 3 , R 4 and R 5 independently are hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 ,
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
comprising reacting a compound of formula III
with a compound of formula IV
wherein Z is OH, or, when R 2 is —S(O) 2 CH 3 or —C(O)R 6 , then Z may also be halogen or a sulfonic acid residue.
23 . A process for the preparation of a compound of formula I in accordance with claim 1
wherein
R 1 is hydrogen or methyl;
R 2 is —S(O) 2 CH 3 or —C(O)R 6 ;
R 3 , R 4 and R 5 independently are hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 ,
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
comprising reacting a compound of formula I wherein R 2 is hydrogen,
with an activated acyl derivative; or by a condensation reaction of an acid using a condensation reagent; or by reaction with an activated sulfonyl derivative; or by reaction with an isocyanate.
24 . A process for the preparation of a compound of formula I in accordance with claim 1
wherein
R 1 is hydrogen or methyl;
R 2 is —S(O) 2 CH 3 or —C(O)R 6 ;
R 3 , R 4 and R 5 independently are hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
R 6 is —C(O)NH 2 or —CH 2 C(O)NH 2 ,
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
comprising reacting a compound of formula I wherein R 2 is hydrogen,
with an activated acyl derivative; or by a condensation reaction of an acid using a condensation reagent; and converting the resulting ester function into a corresponding amide.
25 . A process for the preparation of a compound of formula I in accordance with claim 1
R 1 is hydrogen or methyl;
R 2 is (C 1 -C 3 )-alkyl, —CH 2 C(O)NH 2 or —CH(CH 3 )C(O)NH 2 ;
R 3 , R 4 and R 5 independently are hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
comprising reacting a compound of formula I wherein R 2 is hydrogen, with an alkylating agent selected from the group consisting of alkylating agents include halides, tosylates, mesylates and triflates.
26 . A pharmaceutical composition comprising a compound of formula I
wherein
R 1 is hydrogen or methyl;
R 2 is hydrogen, (C 1 -C 3 )-alkyl, —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R;
R 3 , R 4 and R 5 are each independently hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 ,
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; or
X—X′ is —CH 2 — and Y—Y′ is —CH 2 —CH 2 —C(O)—;
wherein when one of X—X′ and Y—Y′ is —CH 2 —CH 2 — and the other is —CH═CH—, or when both of X—X′ and Y—Y′ are —CH═CH—, then R 2 is —S(O) 2 CH 3 or —C(O)R 6 ; or when X—X′ and Y—Y′ are —CH 2 —C(O)— then R 2 is hydrogen, (C 1 -C 3 )-alkyl, —CH 2 C(O)NH 2 or —CH(CH 3 )C(O)NH 2 ;
or a pharmaceutically acceptable salt thereof
and a pharmaceutically acceptable diluent or carrier therefor.
27 . A method of inhibiting monoamine oxidase B activity comprising administering to a subject a monoamine oxidase B inhibiting amount of a compound of formula I
wherein
R 1 is hydrogen or methyl;
R 2 is hydrogen, (C 1 -C 3 )-alkyl, —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R 6 ;
R 3 , R 4 and R 5 are each independently hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 ,
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
or a pharmaceutically acceptable salt thereof.
28 . A method of treating Alzheimer's disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I
wherein
R 1 is hydrogen or methyl;
R 2 is hydrogen, (C 1 -C 3 )-alkyl, —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R;
R 3 , R 4 and R 5 are each independently hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 ,
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
or a pharmaceutically acceptable salt thereof.
29 . A method of treating senile dementia comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I
wherein
R 1 is hydrogen or methyl;
R 2 is hydrogen, (C 1 -C 3 )-alkyl, —CH 2 C(O)NH 2 , —CH(CH 3 )C(O)NH 2 , —S(O) 2 CH 3 or —C(O)R;
R 3 , R 4 and R 5 are each independently hydrogen, halogen, cyano, (C 1 -C 3 )-alkyl or —O—(C 1 -C 3 )-alkyl;
R 6 is hydrogen, —CH 3 , —CH 2 OCH 3 , —C(O)NH 2 , —CH 2 C(O)NH 2 , —OCH 3 , —NH 2 or —NHCH 2 CH 3 ,
X—X′ is —CH 2 —CH 2 —, —CH═CH— or —CH 2 —C(O)—; and
Y—Y′ is —CH 2 —C(O)—;
or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.